Table 2 CVOTs completed in 2016/17 and published in 2017: comparison of results vs. placebo

Primary Composite MACE

CV death, MI

or stroke

0.86 (0.75–0.97)

0.02^a

CV death, MI or stroke

0.91 (0.83–1.00)

0.06^a

CV death, MI or stroke

0.91 (0.78–1.06)

<0.001

CV death, MI, stroke, UA

and HF

0.98 (0.86–1.11)

0.73

CV death, MI, stroke, UA and coronary re-vascularisation

0.85 (0.79–0.92)

<0.001

Cardiovascular death

Primary

endpoint

0.87 (0.72–1.06)

–

Secondary endpoint

0.88 (0.76–1.02)

–

Primary

endpoint

0.96 (0.76–1.21)

0.71

Secondary endpoint

0.89 (0.71–1.11)

0.29

Secondary endpoint

1.05 (0.88–1.25)

0.62

Myocardial infarction

Primary

endpoint

0.89 (0.73–1.09)

–

Secondary endpoint

0.97 (0.85–1.10)

–

Primary

endpoint

0.85 (0.68–1.06)

0.15

Secondary endpoint

1.12 (0.87–1.46)

0.38

Secondary endpoint

0.73 (0.65–0.82)

<0.001

Stroke

Primary endpoint

0.87 (0.69–1.09)

–

Secondary endpoint

0.85 (0.70–1.03)

–

Primary endpoint

0.90 (0.65–1.23)

0.50

Secondary endpoint

0.97 (0.70–1.33)

0.83

Secondary endpoint

0.79 (0.66–0.95)

0.01

Hospitalisation for unstable angina

–

–

–

–

–

–

Primary

endpoint

0.95 (0.68–1.31)

0.74

Secondary endpoint

1.02 (0.82–1.26)

0.87

Secondary endpoint

0.99 (0.82–1.18)

0.89

Hospitalisation for heart failure

Secondary endpoint

0.67 (0.52–0.87)

–

Secondary endpoint

0.94 (0.78–1.13)

–

–

–

–

Secondary endpoint

0.89 (0.63–1.24)

0.48

–

–

–

Primary composite MACE

26.9^b

11.4

8.5

14.4

9.8

Renal event

19.7^b

0.32

55 (0.7)

–

3.8 (–)

–

– (–)

–

– (–)

–

Acute pancreatitis

0.5^b

0.63

26 (0.4)

–

– (–)

–

– (–)

–

– (–)

–

Hypoglycaemia events

50.0^b

0.20

247 (3.4)^c

–

4.9 (–)^c

<0.001^a

54 (2)^c

0.95

– (–)

–